Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 19 (3) , e110-e116
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Servier
- Roche
- Eli Lilly and Company
- Ipsen
- Sanofi
- Pfizer
- Celgene
- AstraZeneca
- Meso Scale Diagnostics
- Amgen
- Shire
- Merck
- Bayer
This publication has 29 references indexed in Scilit:
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal CancerJAMA, 2017
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal CancerJAMA Oncology, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyThe Lancet Oncology, 2015
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyThe Oncologist, 2012
- Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated AnalysisJNCI: Journal of the National Cancer Institute, 2010
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agentsAnnals of Oncology, 2009
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal CancerPLOS ONE, 2009
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008